Physician profile
John M Lytle
NPI 1467477547
$1,116.92
in general payments reported to CMS, 2019-2025
19 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $25.63 · 2021: $36.95 · 2022: $146 · 2023: $236 · 2024: $200 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $388.19 | 2022-2025 | Azstarys |
| Sobi, INC | $99.23 | 2019-2023 | |
| Sanofi Pasteur INC. | $86.69 | 2019-2025 | |
| Pfizer INC. | $73.20 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $65.26 | 2019 | |
| Glaxosmithkline, LLC. | $62.29 | 2019-2023 | Bexsero |
| Merck Sharp & Dohme LLC | $54.31 | 2019-2023 | Vaxneuvance, Proquad, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $45.82 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $33.71 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals Lp | $31.01 | 2023-2024 | Flumist Quadrivalent |
| Seqirus USA INC | $30.28 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Supernus Pharmaceuticals, INC. | $24.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.73 | 2024 | |
| Verrica Pharmaceuticals INC. | $22.29 | 2024 | Ycanth |
| Rhodes Pharmaceuticals L.P. | $18.21 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $16.46 | 2019 | |
| Shire North American Group INC | $15.99 | 2019 | |
| Adlon Therapeutics L.P. | $13.26 | 2019 | |
| Tris Pharma INC | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lytle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.